Dr. Julia Liu to Present at American College of Gastroenterology Annual Meeting Oct 22, 2012
TORONTO, ONTARIO--(Marketwire - Oct. 18, 2012) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) today announced that Dr. Julia Liu will be presenting new data on the topic "Confocal Laser Endomicroscopy Findings of the Small Intestine in Irritable Bowel Syndrome (IBS) patients" at the American College of Gastroenterology's (ACG) Annual Scientific Meeting in Las Vegas, October 19-24.
The study will be presented in a plenary session on October 23. Her study will also be featured at the ACG press conference entitled "New Technologies Advance Treatment of Gastrointestinal Disorders" on October 21, 2012.
The Company previously announced in September, 2012 that it had entered into an option agreement to acquire the intellectual property rights to this potentially new diagnostic technology identifying IBS invented by Dr. Liu and her fellow University of Alberta inventors Dr. Randall Irvin and Elisabeth Davis.
The ACG Annual Meeting will be the first time that Dr. Liu will present the underlying data of this new technology.
Dr. Julia Liu joined the Faculty of Medicine and Dentistry at the University of Alberta in 2006. As a member of Centre of Excellence for Gastrointestinal Inflammation and Immunity Research, her research efforts have focused on the application of endoscopic methods for the diagnosis and treatment of gastroenterological diseases. She is a recipient of a number of awards, research fellowships and grants including the Research Excellence in Gastroenterology and Liver Diseases (REGAL), and the Harvard Center for Minimal Invasive Surgery Fellowship. Most recently, she is a recipient of the prestigious Canadian Institute of Health Research (CIHR) New Investigator Salary Award. Currently, she serves on a number of committees of gastroenterological societies and reviews manuscripts for a range of journals including the Annals of Internal Medicine, American Journal of Gastroenterology, and Gastrointestinal Endoscopy.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.